Quture International, Inc. / TCLN Announces Pre-Launch Completion of QualOptima Commercial Product
June 12 2012 - 8:00AM
Marketwired
Quture International, Inc. (OTCQB: TCLN) (PINKSHEETS: TCLN) and
Quture, Inc. ("Quture") announce successful completion of product
development between Quture, Keith Candiotti, MD, its Product
Medical Director, and officials of InterSystems Corporation
(www.intersystems.com). Quture previously announced successful
completion of the Product Demonstration Project on March 27, 2012
and migration of its peer review product, both on the InterSystems
technology platform, on April 4, 2012. Following meetings last week
with Dr. Candiotti and InterSystems at the University of Miami,
Miller School of Medicine, Quture now announces final integration
of these applications into the single QualOptima product. This
signals the ability of Quture to move into initial commercial
sales. Continued product development of the next phases will result
in an even more robust software program to become the global
performance enhancement system to transform payment and delivery
systems in health care.
"Quture has worked toward this milestone for over one year, and
having Dr. Candiotti work directly with the software engineers and
sales and marketing experts at InterSystems will lead to major
commercial product advances," said Landon Feazell, CEO of Quture
International. "Quture recognized with InterSystems at both the
HIMSS conference and the InterSystems Global Summit that the need
remains in the hospital market for the peer review product.
Existing and prospective customers are anxiously awaiting peer
review integrated with performance analytics now programmed on the
InterSystems platform, named QualOptima. This integration is now
the backbone of the new 'transformative and disruptive' tool to
enhance clinical performance to achieve optimal patient outcomes.
The Medical Director of InterSystems and Dr. Richard Fantozzi, the
CEO of Quture, Inc., urged the Company to integrate the performance
product with the peer review product to make QualOptima more
immediately valuable to hospitals. By integrating these product
functionalities, the sum is exponentially greater than the parts as
coordinated applications."
Keith A. Candiotti, M.D., is Executive Vice-Chair & Chief
Operating Officer, and Vice-Chair, Clinical Research, Department of
Anesthesiology, Jackson Memorial Hospital and University of Miami
Miller Medical School. His brilliant design of the performance
measurement product integrated with the peer review product secures
QualOptima's immediate value for the short- and long-range future,
no matter how the Supreme Court rules on the healthcare law. The
integrated QualOptima product connects individual patient risk
factors with evidence-based performance measures compared to
patient outcomes, empowering multiple hospital users to use true
clinical knowledge and actionable insight to improve care and
reduce costs.
"These transformative assets are converging on the remarkable
InterSystems technology platform to derive clinical knowledge
solutions," Feazell continued. "Disparate databases and silos of
information have limited our endeavors for over 35 years of
clinical performance measurement in health care. We believe
data-driven clinical decisions by providers, payers and patients
from these sources of previously inaccessible information will
forever change the payment and delivery systems of health care and
health. This is a pivotal juncture in health care and its impact on
the American economy and on the lives of patients and the
professionals devoted to caring for them. We will be proud to soon
introduce these new tools commercially to accomplish our mission
and to exceed and bring new capability to the extensive new federal
and national mandates and standards. These endeavors are converging
to pave the way for other anticipated business opportunities and
reflect our current strategic plans to build long-term shareholder
value."
QUTURE INTERNATIONAL, INC. Quture
International, Inc. is an emerging growth company positioned to
become the leading clinical knowledge company in the world. The
core competence of Quture is clinical performance enhancement to
achieve optimal patient outcomes. Quture's brand is centered on the
value proposition of trust, transparency and independence. As the
free enterprise solution to improving health and health care while
reducing costs, Quture is comprised of a subsidiaries in North
America and Europe for the operations of its software technology
solutions, plans for a "beyond data" consulting and knowledge
applications company, as well as plans for a personalized,
proactive, and predictive medicine company with a virtual community
of members. These subsidiaries will all be affiliated with the Qx
Medical Exchange, which the Company intends to become the largest
medical and health exchange in the world. Quture International is a
Nevada corporation currently trading under the symbol TCLN.
QUTURE, INC. Quture, Inc. is the
operations subsidiary of Quture International, Inc., positioned to
become the international standard in health care performance,
outcomes and analytics. Quture's transformational product
QualOptima operates on the InterSystems technology platform, the
leading software platform globally for health care. QualOptima is
the transcendent healthcare analytics system for performance
enhancement to achieve optimal patient outcomes. The analytics
system measures performance against evidence-based optimal clinical
processes of care. The clinical data repository of QualOptima, the
Qualytx integrated aggregate clinical database, is planned to
become the international common data platform for health and health
care. Qualytx will then be capable of transforming personal health
and health care through knowledge solutions founded on Quture's
proprietary science of knowing what to measure, where that data
resides in disparate databases, using the InterSystems technology
to electronically abstract that data, and converting data to
knowledge and actionable insight with its revolutionary and
proprietary analytics system. As America transitions to payment for
value and U.S. and international pressures converge to measure
performance, Quture will navigate the future of global health and
healthcare quality, patient safety and value.
This release contains forward-looking statements, including,
without limitation, statements concerning our business and possible
or assumed future results of operations. Our actual results could
differ materially from those anticipated in the forward-looking
statements for many reasons including: our ability to continue as a
going concern, adverse economic changes affecting markets we serve;
competition in our markets and industry segments; our timing and
the profitability of entering new markets; greater than expected
costs, customer acceptance of our products or difficulties related
to our integration of the businesses we may acquire; and other
risks and uncertainties as may be detailed from time to time in our
public announcements and SEC filings. Although we believe the
expectations reflected in the forward-looking statements are
reasonable, they relate only to events as of the date on which the
statements are made, and our future results, levels of activity,
performance or achievements may not meet these expectations. We do
not intend to update any of the forward-looking statements after
the date of this document to conform these statements to actual
results or to changes in our expectations, except as required by
law. There is no assurance that a definitive agreement will be
completed.
For Further Information Contact: Constellation Asset
Advisors, Inc. Jens Dalsgaard President +1 (415) 524-8500 Mele
Telitz Director of Communications 303-204-4486 mele@quture.com